Diabetic Foot UlcersPhase 1NCT02652754
Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers
A Phase 1 study testing Granexin® gel in people with Diabetic Foot Ulcers, run by Xequel Bio, Inc. at 3 sites in United States.
Trial summary
The purpose of this study is to determine the systemic exposure of Granexin® gel after topical application to human subjects' diabetic foot ulcers. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetic Foot Ulcers
- What is being tested?
- Granexin® gel
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 3 sitesUnited States
- Study dates
- Sep 2015to May 2018
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 or older
- Established diagnosis of diabetes mellitus (type I or II)
- Glycosylated hemoglobin (HbA1c) value < 10.0% at the screening visit
- Diagnosis of neuropathic foot ulcer(s)
- Designated foot ulcer meets the following criteria at both the screening an baseline visits. If the patient has multiple ulcers, at least one ulcer must meet the following criteria at both the screening and baseline visits: a) Present for at least 4 weeks; b) Full-thickness cutaneous ulcer below the ankle surface; c) University of Texas grade A1; d) Area (after debridement) > 4 square cm; e) Viable, granulating wound (investigator discretion)
- Ankle brachial index 0.7 to 1.3 at both the screening and baseline visits
- Signed informed consent
- Female patients of childbearing potential must have a negative pregnancy test at screening and must agree to use hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence throughout until 2 weeks after the last administration of study drug.
Who cannot join
- Decrease in size of the designated target ulcer(s) by ≥ 30% during the 7-day screening period.
- Impaired cognition determined by clinical investigator
- Cannot tolerate the off-loading method or cannot comply with study-defined standard-of-care treatment.
- Has an ulcer that meets any of the following criteria: a) Shows signs of severe clinical infection, defined as pus oozing from the ulcer site; b) Is positive for β-hemolytic streptococci upon culture; c) Has > 50% slough, significant necrotic tissue, bone, tendon, or capsule exposure; d) Is highly exuding (i.e., requires daily change of dressing)
- Requires total contact cast
- Ankle brachial pressure index <0.7 or > 1.3 or ankle systolic pressure <70 mmHg.
Show all 25Show fewer
- Has a systemic infection
- Has any 1 of the following (only 1 of the 3 tests is required): a) On Doppler waveform analysis of the dorsalis pedis and posterior tibial arteries, a monophasic or biphasic flow (with loss of reverse flow) in either the artery of either foot; b) Toe: bracial index < 0.7 or > 1.3; c) Transcutaneous oxygen pressure < 40 mmHg
- Presence of active systemic or local cancer or tumor of any king (exception: nonmelanoma skin cancer allowable at investigator discretion)
- Congestive heart failure (New York Heart Association class II-IV) or coronary heart disease with ST segment elevation, myocardial infarction or coronary artery bypass graft, or percutaneous transluminal coronary angioplasty within the last 6 months.
- Active osteomyelitis of the foot with the target ulcer(s)
- Active connctive tissue disease
- Acute Charcot's neuro-arthropathy as determined by clinical and/or radiographic examination.
- Active treatment with systemic corticosteroids.
- Previous or current radiation therapy to the distal lower extremity or likelihood to receive this therapy during study participation.
- Pregnant or nursing.
- Uncontrolled anemia (hemoglobin < 10 g/dL in females and < 12 g/dL in males).
- Estimated glomerular filtration rate < 25 g/L.
- Poor nutritional status, defined as an albumin < 25 g/L.
- Significant peripheral edema as per investigator's discretion
- Known inability or unavailability to complete required study visits during study participation.
- A psychiatric condition (e.g., suicidal ideation) or chronic alcohol or drug abuse problem, determined from the patient's medical history, which in the opinion of the investigator, may pose a threat to patient compliance.
- Use of a platelet-derived growth factor within 28 days before screening.
- Use of any investigational drug or therapy within 28 days before screening.
- Has any other factor which may, in the opinion of the investigator, compromise participation and/or follow-up in the study.
Trial locations and contacts
3 sites in 1 country.
United States3 sites
Aiyan Diabetes Center
Augusta, Georgia, 30907
Salem VA Medical Center
Salem, Virginia, 24153
Spartanburg Regional Healthcare System
Spartanburg, South Carolina, 29303
About this study
Official title: Open Label Pharmacokinetic Study of Granexin® Gel in Patients With Diabetic Foot Ulcers
The purpose of this study is to determine the systemic exposure of Granexin® gel after topical application to human subjects' diabetic foot ulcers.
Read the detailed description
The objective of this study is to ascertain the systemic exposure of the active ingredient in Granexin® gel (aCT1 peptide) after topical application to diabetic foot ulcers using pharmacokinetic analysis. It is planned that a total of 16 patients with diabetic foot ulcers will receive Granexin® gel treatment plus standard of care in this one arm study. The study includes a screening period (1 week) and a treatment period (1 week) which occur sequentially for a given patient. The baseline day, which demarcates the beginning of the treatment period, is the designated as Day 0. Screening procedures are initially conducted on Day -7.
A target foot ulcer is identified at screening and patient eligibility is confirmed at screening and then again at the beginning of the Day 0 (baseline) visit. A patient enrolled in the study may have multiple ulcers on the same or either foot; in this case, all ulcers will be treated with Granexin® gel, but only ulcer(s) meeting the following criteria will be designated as the target ulcer(s) and will determine eligibility: >4cm2 in post debridement of at least 4 weeks duration.
The treatment period for a given patient begins on Day 0 and ends one week later; the last scheduled day of the treatment period is designated as Day 7. During the treatment period, each patient is scheduled to receive topical treatment with study drug gel (3 applications total) administered by study staff at scheduled study site visits at each of the following time points: Day 0, Day 3, and Day 7. All patients, regardless of treatment assignment, also receive standard-of-care treatment at scheduled study visits during the treatment period.
Study drug pre-application blood samples will be collected from each patient at Day 0, Day 3, and Day 7. Study drug post-application blood samples will be collected at Day 0 and Day 7 at time points specified in the protocol. These blood samples will be shipped to a designated laboratory for pharmacokinetic analysis.
Safety will be assessed during the treatment period by monitoring adverse events, measuring vital signs at each visit, performing physical examinations, electrocardiograms (ECG), as well as pharmacokinetic (PK) blood analysis.
- Conditions
- Diabetic Foot Ulcers
- Being tested
- Granexin® gel
- Keywords
- Granexin, diabetic foot ulcers, pharmacokinetic study, FirstString Research
- Medical subject headings
- Diabetic Foot
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Granexin® gelDrug
Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
| Study group | Role | What they receive |
|---|---|---|
| Granexin® gel plus standard-of-care | Other | Granexin® gel will be applied topically to diabetic foot ulcer(s) on Day 0 (baseline), Day 3, and Day 7. In addition, standard-of-care treatment will be applied to the ulcer(s) at Screening, Day 0, Day 3, and Day 7. Receives: Drug: Granexin® gel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Measurement of aCT1 peptide (Active Pharmaceutical Ingredient in Granexin) levels in blood
Measured: Day 0
Measurement of aCT1 peptide (Active Pharmaceutical Ingredient in Granexin) levels in blood
Measured: Day 3
Measurement of aCT1 peptide (Active Pharmaceutical Ingredient in Granexin) levels in blood
Measured: Day 7
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2016 (estimated)
- Study startSep 2015
- Primary completionDec 2017
- Study completionMay 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetic Foot UlcersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Xequel Bio, Inc.
- Sponsor type
- University, hospital or other
- Collaborators
- Medical University of South Carolina, Spartanburg Regional Healthcare System
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02652754
- Sponsor's protocol ID
- DFU-PK-300
- Status last verified
- Jul 2018
- First submitted
- 8 Jan 2016
- Last updated
- 1 Aug 2018
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 1 Aug 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Open Label Pharmacokinetic Study of Granexin® Gel in Patients With Diabetic Foot Ulcers
- ClinicalTrials.gov ID
- NCT02652754
- Acronym / sponsor ID
- DFU-PK-300
- Conditions
- Diabetic Foot Ulcers
- Keywords
- Granexin, diabetic foot ulcers, pharmacokinetic study, FirstString Research
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Xequel Bio, Inc.University, hospital or other
- Collaborators
- Medical University of South Carolina, Spartanburg Regional Healthcare System
- Study start
- Sep 2015
- Primary completion
- Dec 2017 (actual)
- Study completion
- May 2018 (actual)
- First posted
- 12 Jan 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the systemic exposure of Granexin® gel after topical application to human subjects' diabetic foot ulcers.
Detailed description
The objective of this study is to ascertain the systemic exposure of the active ingredient in Granexin® gel (aCT1 peptide) after topical application to diabetic foot ulcers using pharmacokinetic analysis. It is planned that a total of 16 patients with diabetic foot ulcers will receive Granexin® gel treatment plus standard of care in this one arm study. The study includes a screening period (1 week) and a treatment period (1 week) which occur sequentially for a given patient. The baseline day, which demarcates the beginning of the treatment period, is the designated as Day 0. Screening procedures are initially conducted on Day -7.
A target foot ulcer is identified at screening and patient eligibility is confirmed at screening and then again at the beginning of the Day 0 (baseline) visit. A patient enrolled in the study may have multiple ulcers on the same or either foot; in this case, all ulcers will be treated with Granexin® gel, but only ulcer(s) meeting the following criteria will be designated as the target ulcer(s) and will determine eligibility: >4cm2 in post debridement of at least 4 weeks duration.
The treatment period for a given patient begins on Day 0 and ends one week later; the last scheduled day of the treatment period is designated as Day 7. During the treatment period, each patient is scheduled to receive topical treatment with study drug gel (3 applications total) administered by study staff at scheduled study site visits at each of the following time points: Day 0, Day 3, and Day 7. All patients, regardless of treatment assignment, also receive standard-of-care treatment at scheduled study visits during the treatment period.
Study drug pre-application blood samples will be collected from each patient at Day 0, Day 3, and Day 7. Study drug post-application blood samples will be collected at Day 0 and Day 7 at time points specified in the protocol. These blood samples will be shipped to a designated laboratory for pharmacokinetic analysis.
Safety will be assessed during the treatment period by monitoring adverse events, measuring vital signs at each visit, performing physical examinations, electrocardiograms (ECG), as well as pharmacokinetic (PK) blood analysis.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Granexin® gel plus standard-of-care | Other | Drug: Granexin® gelGranexin® gel will be applied topically to diabetic foot ulcer(s) on Day 0 (baseline), Day 3, and Day 7. In addition, standard-of-care treatment will be applied to the ulcer(s) at Screening, Day 0, Day 3, and Day 7. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Age 18 or older
- Established diagnosis of diabetes mellitus (type I or II)
- Glycosylated hemoglobin (HbA1c) value < 10.0% at the screening visit
- Diagnosis of neuropathic foot ulcer(s)
- Designated foot ulcer meets the following criteria at both the screening an baseline visits. If the patient has multiple ulcers, at least one ulcer must meet the following criteria at both the screening and baseline visits: a) Present for at least 4 weeks; b) Full-thickness cutaneous ulcer below the ankle surface; c) University of Texas grade A1; d) Area (after debridement) > 4 square cm; e) Viable, granulating wound (investigator discretion)
Key exclusion criteria (25 listed)
- Decrease in size of the designated target ulcer(s) by ≥ 30% during the 7-day screening period.
- Impaired cognition determined by clinical investigator
- Cannot tolerate the off-loading method or cannot comply with study-defined standard-of-care treatment.
- Has an ulcer that meets any of the following criteria: a) Shows signs of severe clinical infection, defined as pus oozing from the ulcer site; b) Is positive for β-hemolytic streptococci upon culture; c) Has > 50% slough, significant necrotic tissue, bone, tendon, or capsule exposure; d) Is highly exuding (i.e., requires daily change of dressing)
- Requires total contact cast
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Granexin® gelGranexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7. | Drug | Granexin® gel plus standard-of-care |
Primary outcome
Measurement of aCT1 peptide (Active Pharmaceutical Ingredient in Granexin) levels in blood
Time frame: Day 0
Measurement of aCT1 peptide (Active Pharmaceutical Ingredient in Granexin) levels in blood
Time frame: Day 3
Measurement of aCT1 peptide (Active Pharmaceutical Ingredient in Granexin) levels in blood
Time frame: Day 7
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Aug 2018.
Related trials for Diabetic Foot Ulcers
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Active, not recruiting
Wearable Insoles for Recurrent Diabetic Ulcer Prevention
Diabetes, Peripheral Neuropathy
Active, not recruiting
Evaluation of Personalized Nutritional Intervention on Wound Healing of Cutaneous Ulcers in Diabetics
Foot, Diabetic
Not yet recruiting
Efficacy Evaluation of Turmeric-Derived Nanoparticle Hydrogel for the Treatment of Diabetic Foot Ulcer Wounds
Diabete Mellitus
Not yet recruiting
Better Care Closer to Home: Enhancing Primary and Community Care
Diabetic Foot Disease, Recurrence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Granexin® gel in people with Diabetic Foot Ulcers, run by Xequel Bio, Inc. at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measurement of aCT1 peptide (Active Pharmaceutical Ingredient in Granexin) levels in blood (time frame: Day 0). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Aug 2018.